First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial-Reference-Cited by-同舟云学术

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Published:2022-02 Issue:2 Volume:17 Page:289-308
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Paz-Ares Luis G.,Ramalingam Suresh S.,Ciuleanu Tudor-Eliade,Lee Jong-Seok,Urban Laszlo,Caro Reyes Bernabe,Park Keunchil,Sakai Hiroshi,Ohe Yuichiro,Nishio Makoto,Audigier-Valette Clarisse,Burgers Jacobus A.,Pluzanski Adam,Sangha Randeep,Gallardo Carlos,Takeda Masayuki,Linardou Helena,Lupinacci Lorena,Lee Ki Hyeong,Caserta Claudia,Provencio Mariano,Carcereny Enric,Otterson Gregory A.,Schenker Michael,Zurawski Bogdan,Alexandru Aurelia,Vergnenegre Alain,Raimbourg Judith,Feeney Kynan,Kim Sang-We,Borghaei Hossein,O'Byrne Kenneth John,Hellmann Matthew D.,Memaj Arteid,Nathan Faith Ellen,Bushong Judith,Tran Phuong,Brahmer Julie R.,Reck Martin

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference38 articles.

1. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

2. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

3. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

4. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

5. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC;Socinski;N Engl J Med,2018

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta-analysis of the efficacy of programmed cell death 1/its ligand inhibitors plus cytotoxic T-lymphocyte-associated antigen 4 inhibitors in non-small cell lung cancer;Frontiers in Pharmacology;2024-02-05

2. Surgery for oligometastatic non–small cell lung cancer;The Journal of Thoracic and Cardiovascular Surgery;2024-02

3. Impact of Antibiotics, Corticosteroids, and Microbiota on Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer;2024-01-30

4. First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study;Japanese Journal of Clinical Oncology;2024-01-25

5. Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review;Medicine;2024-01-19